A DNA Vaccine against Yellow Fever Virus: Development and Evaluation

PLoS Neglected Tropical Diseases

Volumn 9, Issue 4, 2015, Pages

  Maciel, Milton ^a,g   Cruz, Fábia da Silva Pereira ^b   Cordeiro, Marli Tenório ^b,c   da Motta, Márcia Archer ^d   Cassemiro, Klécia Marília Soares de Melo ^b   Maia, Rita de Cássia Carvalho ^e   de Figueiredo, Regina Célia Bressan Queiroz ^b   Galler, Ricardo ^d   Freire, Marcos da Silva ^d   August, Joseph Thomas ^a   Marques, Ernesto T A ^a,b,f   Dhalia, Rafael ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Central Public health Laboratory/LAcen   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e UNIVERSIDADE FEDERAL RURAL DE PERNAMBUCO   (Brazil)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; VIRUS ENVELOPE PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLAVIVIRUS INFECTION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; T LYMPHOCYTE ACTIVATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING; YELLOW FEVER VIRUS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; FEMALE; IMMUNOLOGY; T LYMPHOCYTE; VACCINATION; VIROLOGY; YELLOW FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84929497428     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003693     Document Type: Article

References (44)

1. Julander JG, Experimental therapies for yellow fever. Antiviral Res. 2013;97(2):169–79. doi: 10.1016/j.antiviral.2012.12.002 23237991
2. World Health Organization, Division of Epidemiological Surveillance and Health Situation Trend Assessment. Global health situation and projections—-estimates. Geneva, Switzerland: World Health Organization; 1992.
3. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005;1(5): 207–214. 17012867
4. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59(6): 895–900. 6978196
5. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J, Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998;56(2): 159–167. 9746073
6. Breugelmans JG, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31(14):1819–29. doi: 10.1016/j.vaccine.2013.01.054 23395587
7. Miyaji KT, Luiz AM, Lara AN, do Socorro Souza Chaves T, Piorelli RD, Lopes MH, et al. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more. Hum Vaccin Immunother. 2013;9(2).
8. Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, et al. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg. 2012;106(7):437–44. doi: 10.1016/j.trstmh.2012.04.002 22627101
9. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review. Curr Drug Saf. 2011;6(3):145–54. 22122389
10. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002;66(5): 533–541. 12201587
11. Lefeuvre A, Marianneau P, Deubel V, Current Assessment of Yellow Fever and Yellow Fever Vaccine. Curr Infect Dis Rep 2004;6(2): 96–104. 15023271
12. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al. Brazilian Yellow Fever Vaccine Evaluation. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358(9276): 91–97. 11463409
13. Lewis PJ, Babiuk LA, DNA vaccines: a review. Adv Virus Res 1999;54: 129–188. 10547676
14. Li L, Saade F, Petrovsky N, The future of human DNA vaccines. J Biotechnol. 2012;162(2–3):171–82. doi: 10.1016/j.jbiotec.2012.09.018 23036927
15. Robinson HL, DNA vaccines: basic mechanism and immune responses (Review). Int J Mol Med 1999;4(5): 549–555. 10534580
16. Schultz J, Dollenmaier G, Molling K, Update on antiviral DNA vaccine research (1998–2000). Intervirology 2000;43(4–6): 197–217. 11251381
17. Lu Y, Raviprakash K, Leao IC, Chikhlikar PR, Ewing D, Anwar A, et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 2003;21(17–18): 2178–2189. 12850357
18. Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000;18(22): 2426–2434. 10738100
19. Konishi E, Terazawa A, Fujii A, Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine 2003;21(25–26): 3713–3720.
20. Konishi E, Yamaoka M, Khin Sane W, Kurane I, Mason PW, Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol 1998;72(6): 4925–4930. 9573260
21. Wu CJ, Li TL, Huang HW, Tao MH, Chan YL, Development of an effective Japanese encephalitis virus-specific DNA vaccine. Microbes Infect 2006;8(11): 2578–2586. 16949850
22. Anwar A, Chandrasekaran A, Ng ML, Marques E, August JT, West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology 2005;332(1): 66–77. 15661141
23. Konishi E, Yamaoka M, Kurane I, Mason PW, A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 2000;18(11–12): 1133–1139.
24. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, et al. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 2001;290(1): 74–82. 11883007
25. Marques ET, JrChikhlikar P, de Arruda LB, Leao IC, Lu Y, Wong J, et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003;278(39): 37926–37936. 12824194
26. de Arruda LB, Chikhlikar PR, August JT, Marques ET, DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004;112(1): 126–133. 15129672
27. Lippincott-Schwartz J, Fambrough DM, Lysosomal membrane dynamics: structure and interorganellar movement of a major lysosomal membrane glycoprotein. J Cell Biol 1986;102(5): 1593–1605. 2871029
28. Drake JR, Lewis TA, Condon KB, Mitchell RN, Webster P, Involvement of MIIC-like late endosomes in B cell receptor-mediated antigen processing in murine B cells. J Immunol 1999;162(2): 1150–1155. 9916746
29. Kleijmeer MJ, Morkowski S, Griffith JM, Rudensky AY, Geuze HJ, Major histocompatibility complex class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments. J Cell Biol 1997;139(3): 639–649. 9348281
30. Arruda LB, Sim D, Chikhlikar PR, Maciel M, JrAkasaki K, August JT, et al. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J Immunol 2006;177(4): 2265–2275. 16887987
31. Chikhlikar P, Barros de Arruda L, Agrawal S, Byrne B, Guggino W, August JT, et al. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 2004;323(2): 220–232. 15193918
32. Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 1999;17(9–10):1042–6.
33. Maciel M., JrKellathur SN, Chikhlikar P, Dhalia R, Sidney J, Sette A, et al. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 2008;378(1):105–17. doi: 10.1016/j.virol.2008.04.043 18579176
34. WHO. Requirements for the production and control of yellow fever vaccine. (Requirements for Biological Substances No. 3.) In: WHO Expert Committee on Biological Standardization. Forty-sixth report. Geneva, World Health Organization, 1998, Annex 2 (WHO Technical Report Series, No. 872).
35. Barrett AD, Gould EA, Comparison of neurovirulence of different strains of yellow fever virus in mice. J Gen Virol 1986;67(Pt 4)(Pt 4):631–7.
36. Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002;51(RR-17): 1–11; quiz CE11-14.
37. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA, Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996;156(9): 3151–3158. 8617935
38. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K, Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1003;11: 729–766. 7682817
39. van Der Most RG, Murali-Krishna K, Ahmed R, Strauss JH, Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 2000;74(17):8094–101 10933719
40. Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M, Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 1986;67(Pt 2)(Pt 2):229–34.
41. Schlesinger JJ, Brandriss MW, Walsh EE, Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol 1985;135(4):2805–9. 4031501
42. Putnak JR, Schlesinger JJ, Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol 1990;71 (Pt 8)(Pt 8):1697–702.
43. Despres P, Dietrich J, Girard M, Bouloy M, Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. J Gen Virol 1991;72 (Pt 11)(Pt 11):2811–6. 1834798
44. Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, Rice CM, et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 1992;187(1):290–7. 1736531